Challenging sequential approach to treatment resistant depression: Cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial

European Neuropsychopharmacology

Volumn 23, Issue 12, 2013, Pages 1739-1746

  Olgiati, Paolo ^a   Bajo, Emanuele ^a   Bigelli, Marco ^a   Montgomery, Stuart ^b   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Antidepressants; Cost benefit; Depression; Pharmacoeconomics; Switching

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MEDICATION THERAPY MANAGEMENT; OUTPATIENT; PRIORITY JOURNAL; RELAPSE; REMISSION; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

ANTIDEPRESSANTS; COST-BENEFIT; DEPRESSION; PHARMACOECONOMICS; SWITCHING;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; YOUNG ADULT;

EID: 84887610914     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.08.008     Document Type: Article

References (36)

1. Andronis L., Barton P., Bryan S. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technol. Assess. 2009, 13(iii, ix-xi):1-61.
2. Aydemir O., Ergun H., Soygur H., Kesebir S., Tulunay C. [Quality of life in major depressive disorder: a cross-sectional study]. Turk Psikiyatri Derg. 2009, 20:205-212.
3. Bender A., Farvolden P. Depression and the workplace: a progress report. Curr. Psychiatry Rep. 2008, 10:73-79.
4. Buist-Bouwman M.A., De Graaf R., Vollebergh W.A., Alonso J., Bruffaerts R., Ormel J. Functional disability of mental disorders and comparison with physical disorders: a study among the general population of six European countries. Acta Psychiatr. Scand. 2006, 113:492-500.
5. Cipriani A., Geddes J.R., Furukawa T.A., Barbui C. Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can. J. Psychiatry 2007, 52:553-562.
6. Cuffel B.J., Azocar F., Tomlin M., Greenfield S.F., Busch A.B., Croghan T.W. Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. J. Clin. Psychiatry 2003, 64:397-402.
7. Driscoll H.C., Basinski J., Mulsant B.H., Butters M.A., Dew M.A., Houck P.R., Mazumdar S., Miller M.D., Pollock B.G., Stack J.A., Schlernitzauer M.A., Reynolds C.F. Late-onset major depression: clinical and treatment-response variability. Int. J. Geriatr. Psychiatry 2005, 20:661-667.
8. Fischer L.R., Wei F., Solberg L.I., Rush W.A., Heinrich R.L. Treatment of elderly and other adult patients for depression in primary care. J. Am. Geriatr. Soc. 2003, 51:1554-1562.
9. Fox H. The natural course of depression: Kraepelin and beyond. Harv. Rev. Psychiatry 2002, 10:249-253.
10. Golenko-Ginzburg D. On the distribution of activity time in PERT. Journal of the Operational Research Society 1988, 39:767-771.
11. Kirsch I., Deacon B., Huedo-Medina T., Scoboria A., Moore T., Johnson B. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med. 2008, 5:e45.
12. Llorca P.M., Fernandez J.L. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int. J. Clin. Pract. 2007, 61:702-710.
13. Machado M., Iskedjian M., Ruiz I., Einarson T.R. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr. Med. Res. Opin. 2006, 22:1825-1837.
14. Olgiati P., Bajo E., Bigelli M., De Ronchi D., Serretti A. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 36:147-154.
15. *D study. Neuropsychopharmacology 2009, 34:2227-2236.
16. Posternak M.A., Miller I. Untreated short-term course of major depression: a meta-analysis of outcomes from studies using wait-list control groups. J. Affect. Disord. 2001, 66:139-146.
17. Posternak M.A., Solomon D.A., Leon A.C., Mueller T.I., Shea M.T., Endicott J., Keller M.B. The naturalistic course of unipolar major depression in the absence of somatic therapy. J. Nerv. Ment. Dis. 2006, 194:324-329.
18. Revicki D., Wood M. Patient-assigned health state utilities for depression related outcomes: differences by depression severity and antidepressant medications. J. Affect. Disord. 1998, 48:25-36.
19. *D report. Am. J. Psychiatry 2006, 163:1905-1917.
20. Rytsala H.J., Melartin T.K., Leskela U.S., Sokero T.P., Lestela-Mielonen P.S., Isometsa E.T. Functional and work disability in major depressive disorder. J. Nerv. Ment. Dis. 2005, 193:189-195.
21. Sapin C., Fantino B., Nowicki M.L., Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual. Life Outcomes 2004, 2:20.
22. Sarnes M.W., Frankum L.E. Pharmacoeconomic evaluation of antidepressant therapies. Manag. Care 2004, 13:34-41.
23. Serretti A., Olgiati P., Bajo E., Bigelli M., De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J. Biol. Psychiatry 2011.
24. Simon G.E., Savarino J., Operskalski B., Wang P.S. Suicide risk during antidepressant treatment. Am. J. Psychiatry 2006, 163:41-47.
25. Soeteman D.I., Timman R., Trijsburg R.W., Verheul R., Busschbach J.J. Assessment of the burden of disease among inpatients in specialized units that provide psychotherapy. Psychiatr. Serv. 2005, 56:1153-1155.
26. Souery D., Serretti A., Calati R., Oswald P., Massat I., Konstantinidis A., Linotte S., Bollen J., Demyttenaere K., Kasper S., Lecrubier Y., Montgomery S., Zohar J., Mendlewicz J. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J. Clin. Psychopharmacol. 2011, 31:512-516.
27. Souery D., Serretti A., Calati R., Oswald P., Massat I., Konstantinidis A., Linotte S., Kasper S., Montgomery S., Zohar J., Mendlewicz J. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J. Biol. Psychiatry 2011, 12:364-375.
28. Uher R., Mors O., Rietschel M., Rajewska-Rager A., Petrovic A., Zobel A., Henigsberg N., Mendlewicz J., Aitchison K.J., Farmer A., McGuffin P. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J. Clin. Psychiatry 2011, 72:1478-1484.
29. Ustun T.B., Ayuso-Mateos J.L., Chatterji S., Mathers C., Murray C.J. Global burden of depressive disorders in the year 2000. Br. J. Psychiatry 2004, 184:386-392.
30. Wade A., Despiegel N., Heldbo Reines E. Escitalopram in the long-term treatment of major depressive disorder. Ann. Clin. Psychiatry 2006, 18:83-89.
31. Wade A.G., Schlaepfer T.E., Andersen H.F., Kilts C.D. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). J. Psychiatr. Res 2009, 43:568-575.
32. *D report. Am. J. Psychiatry 2007, 164:1189-1197.
33. *D report. Int. J. Neuropsychopharmacol. 2009, 12:459-473.
34. Watkins K.E., Burnam M.A., Orlando M., Escarce J.J., Huskamp H.A., Goldman H.H. The health value and cost of care for major depression. Value Health 2009, 12:65-72.
35. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russell L.B. Recommendations of the panel on cost-effectiveness in health and medicine. J. Am. Med. Assoc. 1996, 276:1253-1258.
36. Whiteford H.A., Harris M.G., McKeon G., Baxter A., Pennell C., Barendregt J.J., Wang J. Estimating remission from untreated major depression: a systematic review and meta-analysis. Psychol. Med. 2012, 1-17.